Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 203 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Sacituzumab Govitecan Improves Outcomes Over Single-Agent Chemotherapy in Patients with Pretreated... March 5, 2024 Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare... July 26, 2023 FDA Approves First Immunotherapy Treatment For Breast Cancer March 11, 2019 EMA Recommends Granting a Marketing Authorisation for Toripalimab August 21, 2024 Load more HOT NEWS Coping With Cancer Recurrence: My Perspective As Both a Patient and... Potential for Larger Gene Panels to Increase the Number of Molecularly... After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms An Updated Overview of Estimates for Cancer Incidence and Mortality in...
